Aspen gets regulatory nod in Brazil and SA for generic semaglutide

Drugmaker Aspem eyes further registrations as global demand for GLP-1 therapies surges

Aspen gets regulatory nod in Brazil and SA for generic semaglutide
Drugmaker Aspem eyes further registrations as global demand for GLP-1 therapies surges